BEIJING, May 06, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208.
CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis. Its tumor-restricted expression and functional role in cancer biology make CDH17 an attractive and differentiated target for ADC therapy, which can be developed for the treatment of gastrointestinal cancers, including colorectal, gastric, pancreatic ductal adenocarcinoma, and biliary tract cancer. Currently, there are no approved CDH17 targeted ADCs globally.
ICP-B208 is a novel ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house developed payload via a protease-cleavable linker. This design enables significantly enhanced tumor-killing effects with improved stability and safety. Preclinical studies show that ICP-B208 demonstrates good anti-tumor activity even in CDH17-low tumors, and improved cell killing activity compared to similar drugs.
ICP-B208 is the second novel ADC to enter into clinical development by the Company’s in-house developed ADC platform, following ICP-B794, a novel B7-H3 targeted ADC. As the platform continues to evolve, the Company is poised to expand its portfolio with multiple differentiated ADC candidates.
Dr. Jasmine Cui, Co-Founder, Chairwoman, and CEO of InnoCare, said, “The approval of the clinical trial of ICP-B208 marks another milestone in our solid tumor pipeline and validates the huge drug development potential of our ADC platform. We will continue to expand our portfolio with multiple ADC candidates and bring new hope to cancer patients worldwide.”
About InnoCare Pharma
InnoCare (SSE: 688428; HKEX: 9969) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing innovative drugs for the treatment of cancers and autoimmune diseases, two therapeutic areas with unmet medical needs worldwide. InnoCare has established comprehensive innovation platforms for drug discovery. To date, the Company has developed a robust product pipeline comprising three approved drugs (orelabrutinib, tafasitamab and zurletrectinib), more than ten innovative drug candidates in clinical development, and multiple programs in preclinical stages. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. For more information about InnoCare, please visit https://www.innocarepharma.com/en and follow us on LinkedIn.
InnoCare Forward-looking Statements
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
| Contact |
||
| Media | Investors | |
| Chunhua Lu | ||
| 86-10-66609879 | 86-10-66609999 | |
| chunhua.lu@innocarepharma.com | ir@innocarepharma.com |
